| 000 | 01879 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250517223849.0 | ||
| 264 | 0 | _c20191022 | |
| 008 | 201910s 0 0 eng d | ||
| 022 | _a1879-1484 | ||
| 024 | 7 |
_a10.1016/j.atherosclerosis.2018.05.047 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMcKay, Ailsa J | |
| 245 | 0 | 0 |
_aUniversal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis. _h[electronic resource] |
| 260 |
_bAtherosclerosis _c08 2018 |
||
| 300 |
_a434-443 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 |
_aBlood Chemical Analysis _xeconomics |
| 650 | 0 | 4 |
_aCholesterol _xblood |
| 650 | 0 | 4 | _aClinical Decision-Making |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 |
_aDNA Mutational Analysis _xeconomics |
| 650 | 0 | 4 | _aDecision Support Techniques |
| 650 | 0 | 4 | _aDecision Trees |
| 650 | 0 | 4 | _aGenetic Markers |
| 650 | 0 | 4 | _aGenetic Predisposition to Disease |
| 650 | 0 | 4 | _aHealth Care Costs |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHyperlipoproteinemia Type II _xblood |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 | _aMarkov Chains |
| 650 | 0 | 4 |
_aMass Screening _xeconomics |
| 650 | 0 | 4 | _aModels, Economic |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aQuality of Life |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aUnited Kingdom |
| 700 | 1 | _aHogan, Helen | |
| 700 | 1 | _aHumphries, Steve E | |
| 700 | 1 | _aMarks, Dalya | |
| 700 | 1 | _aRay, Kausik K | |
| 700 | 1 | _aMiners, Alec | |
| 773 | 0 |
_tAtherosclerosis _gvol. 275 _gp. 434-443 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.atherosclerosis.2018.05.047 _zAvailable from publisher's website |
| 999 |
_c28564273 _d28564273 |
||